Quetiapine-induced cervical dystonia

2015 ◽  
Vol 26 (3) ◽  
pp. 311-312 ◽  
Author(s):  
Grace Tso ◽  
Uday Kolur
Keyword(s):  
Side Effects ◽  
Cervical Dystonia ◽  
Second Generation ◽  
Risk Profile ◽  
Extrapyramidal Side Effects ◽  
Second Generation Antipsychotic

Objective: Our objective was to report and describe a case of quetiapine-induced dystonia in an older lady with psychosis. Quetiapine is a second-generation antipsychotic and known to be rare in causing extrapyramidal side effects with rates similar to placebo. Conclusions: There have been few documented cases of quetiapine-induced dystonia. It is important to be vigilant and consider the development of dystonia in patients who may not fit the typical risk profile.

scholarly journals Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons

2010 ◽  
Vol 38 (1) ◽  
pp. 167-177 ◽  
Author(s):  
Christine Rummel-Kluge ◽  
Katja Komossa ◽  
Sandra Schwarz ◽  
Heike Hunger ◽  
Franziska Schmid ◽  
...  
Keyword(s):  
Systematic Review ◽  
Side Effects ◽  
Antipsychotic Drugs ◽  
Second Generation ◽  
Meta Analysis ◽  
Extrapyramidal Side Effects ◽  
Second Generation Antipsychotic

scholarly journals Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine

PLoS ONE ◽  
2013 ◽  
Vol 8 (1) ◽  
pp. e53459 ◽  
Author(s):  
Heidi N. Boyda ◽  
Ric M. Procyshyn ◽  
Catherine C. Y. Pang ◽  
Erin Hawkes ◽  
Daniel Wong ◽  
...  
Keyword(s):  
Side Effects ◽  
Antipsychotic Drugs ◽  
Second Generation ◽  
The Novel ◽  
Metabolic Side Effects ◽  
Second Generation Antipsychotic

scholarly journals Extrapyramidal side-effects of antipsychotics in a randomised trial

2008 ◽  
Vol 193 (4) ◽  
pp. 279-288 ◽  
Author(s):  
Del D. Miller ◽  
Stanley N. Caroff ◽  
Sonia M. Davis ◽  
Robert A. Rosenheck ◽  
Joseph P. McEvoy ◽  
...  
Keyword(s):  
Side Effects ◽  
Concomitant Medication ◽  
First Generation ◽  
Second Generation ◽  
Rating Scales ◽  
Mixed Model ◽  
Randomised Trial ◽  
Extrapyramidal Side Effects ◽  
Second Generation Antipsychotics ◽  
Secondary Analyses

BackgroundThere are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs.AimsTo compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia.MethodIncidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. Mixed model analyses of change in rating scales from baseline were also conducted.ResultsThere were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing second-generation antipsychotics with perphenazine or comparing between second-generation antipsychotics. Secondary analyses revealed greater rates of concomitant antiparkinsonism medication among individuals on risperidone and lower rates among individuals on quetiapine, and lower rates of discontinuation because of parkinsonism among people on quetiapine and ziprasidone. There was a trend for a greater likelihood of concomitant medication for akathisia among individuals on risperidone and perphenazine.ConclusionsThe incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second-generation antipsychotics in people with schizophrenia.

Metabolic side effects of second generation antipsychotic drugs in adolescents

2013 ◽  
Author(s):  
Iuliana Dobrescu ◽  
Florina Rad ◽  
Gianina Cristina Anghel ◽  
Cristina Petrescu-Ghenea ◽  
Carmen Trutescu
Keyword(s):  
Side Effects ◽  
Antipsychotic Drugs ◽  
Second Generation ◽  
Metabolic Side Effects ◽  
Second Generation Antipsychotic
Sign in / Sign up

Export Citation Format

Share Document